NewLeaf Symbiotics

St. Louis, United States Founded: 2011 • Age: 15 yrs
Crop inputs are supplied using beneficial plant bacteria for agriculture.
Annual revenue - Latest available
Total funding $181.0M 11 rounds
Employees - Tracked headcount
Investors 13 Known backers
Products 6 Services tracked
Competitors 10 Brand Intelligence

About NewLeaf Symbiotics

NewLeaf Symbiotics is a company based in St. Louis (United States) founded in 2011 by Stephen Kahn. NewLeaf Symbiotics has raised $181 million across 11 funding rounds from investors including SABIC, Bayer and Monsanto. NewLeaf Symbiotics has completed 1 acquisition, including Intuitive Genomics. NewLeaf Symbiotics offers products and services including TS201 Corn Bioinsecticide, Terrasym 450 Corn Biostimulant, Terrasym 401 Soybean Biostimulant, TS601 Biofungicide, and Terrasym 402 Peanut Biostimulant. NewLeaf Symbiotics operates in a competitive market with competitors including Pivot Bio, Ginkgo Bioworks, Kula Bio, BioConsortia and Pluton Biosciences, among others.

  • Headquarter St. Louis, United States
  • Founders Stephen Kahn
  • Sectors
    Chemicals & Materials
    Agriculture
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Newleaf Symbiotics
Operational Areas
Chemicals & Materials → Industrial & Technical Services Unlock Sub-Sector Unlock Segment
Agriculture → Agricultural Technology & Innovation Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $181 M (USD)

    in 11 rounds

  • Latest Funding Round
    $47.01 M (USD), Series D

    Dec 12, 2023

  • Investors
    SABIC

    & 12 more

  • Employee Count
    Not available
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of NewLeaf Symbiotics

NewLeaf Symbiotics offers a comprehensive portfolio of products and services, including TS201 Corn Bioinsecticide, Terrasym 450 Corn Biostimulant, Terrasym 401 Soybean Biostimulant, TS601 Biofungicide, and Terrasym 402 Peanut Biostimulant.

Product name locked
Category locked
Primary

Protects corn from pests like CRW to increase yields.

Product name locked
Category locked
Locked

Enhances corn growth and yields through biological application.

Product name locked
Category locked
Locked

Improves soybean productivity in various field conditions.

Product name locked
Category locked
Locked

Controls fungal issues in soybean crops effectively.

Product name locked
Category locked
Locked

Boosts peanut yields by enhancing soil and plant health.

Product name locked
Category locked
Locked

Supports tomato transplant growth for better crop performance.

People of NewLeaf Symbiotics

Headcount 10-50
Employee Profiles 18
Board Members and Advisors 4
Employee Profiles
People
C. Michael McFatrich
VP, Business Strategy & Development
People
David Purschke
VP, Finance
People
Brent Smith
President & CEO
People
Natalie Breakfield
VP, Research & Discovery

Unlock access to complete

Funding Insights of NewLeaf Symbiotics

NewLeaf Symbiotics has successfully raised a total of $181M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $47.01 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in NewLeaf Symbiotics

NewLeaf Symbiotics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include SABIC, Bayer and Monsanto.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Limited information is provided about Otter Capital's activities.
Locked Locked Locked
Stage agnostic venture capital firm
Locked Locked Locked
Venture capital firm investing in life sciences sector
Locked Locked Locked
Premium access

Investor details for NewLeaf Symbiotics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by NewLeaf Symbiotics

NewLeaf Symbiotics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Intuitive Genomics.

Investments
Premium access

Investment portfolio details for NewLeaf Symbiotics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Custom bioinformatics solutions are provided for genome-scale data analysis.
Locked Locked 2010 Locked
Premium access

Complete acquisition details for NewLeaf Symbiotics

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - NewLeaf Symbiotics

Premium access

Detailed financials for NewLeaf Symbiotics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Newleaf Symbiotics Comparisons

NewLeaf Symbiotics Primary company
Description
Crop inputs are supplied using beneficial plant bacteria for...
Location
St. Louis, United States
Founded Year
2011
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for NewLeaf Symbiotics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of NewLeaf Symbiotics

NewLeaf Symbiotics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pivot Bio, Ginkgo Bioworks, Kula Bio, BioConsortia and Pluton Biosciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Nitrogen-fixing microbes for corn crop nutrition are developed and applied.
Locked Locked Locked
Gene editing-based cultured ingredients are provided for agriculture.
Locked Locked Locked
Manufacturer of microbial crop nutrition products
Locked Locked Locked
Microbial biotech solutions for enhancing crop yields are developed.
Locked Locked Locked
Assay-based microbial research services are offered for industrial applications.
Premium access

Detailed competitors of NewLeaf Symbiotics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Newleaf Symbiotics

Premium access

Complete news archive for NewLeaf Symbiotics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about NewLeaf Symbiotics

NewLeaf Symbiotics was founded in 2011.

NewLeaf Symbiotics is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.

Brent Smith is the current CEO of NewLeaf Symbiotics.

NewLeaf Symbiotics is a funded company, having raised a total of $181M across 11 funding rounds to date.

NewLeaf Symbiotics was founded in 2011 and is based in St. Louis, United States. Operations focus on the agriculture sector, where crop inputs are developed using Pink Pigmented Facultative Methylotrophs (PPFMs), a family of naturally occurring beneficial plant bacteria. These inputs are applied to seeds at specified concentrations to support plant growth, vigor, health, and yield increases. The company serves farming applications through these microbial solutions.

NewLeaf Symbiotics's top competitors include Ginkgo Bioworks, Pivot Bio and Kula Bio.

NewLeaf Symbiotics offers TS201 Corn Bioinsecticide, Terrasym 450 Corn Biostimulant, Terrasym 401 Soybean Biostimulant, TS601 Biofungicide, and 2 more products and services.

NewLeaf Symbiotics has made 1 acquisition, including Intuitive Genomics.

NewLeaf Symbiotics has 13 investors. Key investors include SABIC, Bayer, Monsanto, Otter Capital, and S2G Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available